skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Transluminally Placed Endovascular Grafts for Venous Lesions in Patients on Hemodialysis

Abstract

This report summarizes a feasibility study of transluminally placed endovascular grafts (TPEG) using pre-expanded polytetrafluoroethylene (PTFE) to treat venous abnormalities inpatients on hemodialysis. Seventeen patients with peripheral(n = 11) or central (n = 6) venous lesions were treated with TPEG devices. Covered Gianturco stents were used for the peripheral lesions and covered Palmaz stents were used for central lesions. Venous abnormalities included vascular rupture after balloon angioplasty or surgical thrombectomy (n = 4),stenosis associated with an aneurysm (n = 2) and occlusive disease and central stenoses not responsive to balloon angioplasty (n = 11). The mean primary patency period was 37 days. The mean secondary patency period was 215 days. At 60,180, and 360 days the primary and secondary patency rates were 40%,32%, and 32%, and 70%, 55%, and 39%, respectively. Follow-up studies have shown various outcomes of the implanted TPEG devices,which have included stenoses within the TPEG (n = 2),stenoses central to the TPEG (n = 1), stenoses peripheral to the TPEG (n = 3), acute thrombosis extending to the TPEG without a stenosis (n = 1), graft abandoned with patent TPEG (n = 6), and TPEG patent within primary patency period at last follow-up (n =4). The TPEGmore » devices, made with pre-expanded PTFE, appear safe in the short term, do not prevent progressive dialysis access site failure, and need to be compared to PTA and endovascular stenting in a randomized prospective trial.« less

Authors:
 [1];  [2]
  1. Radiology Associates, P.C., P.O.Box 482, Eugene, OR 97440 (United States)
  2. GoodSamaritan Hospital, 1015 NW 22nd, Portland, OR 97210, Department of Radiology (United States)
Publication Date:
OSTI Identifier:
21088371
Resource Type:
Journal Article
Journal Name:
Cardiovascular and Interventional Radiology
Additional Journal Information:
Journal Volume: 26; Journal Issue: 4; Other Information: DOI: 10.1007/s00270-003-2705-y; Copyright (c) 2003 Springer-Verlag New York, Inc.; www.springer-ny.com; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0174-1551
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; DIALYSIS; EQUIPMENT; FEASIBILITY STUDIES; GRAFTS; PATIENTS; POLYTETRAFLUOROETHYLENE; RUPTURES; SURGERY; VASCULAR DISEASES

Citation Formats

Quinn, S.F., E-mail: squinn@peacehealth.org, Kim, J, and Sheley, R C. Transluminally Placed Endovascular Grafts for Venous Lesions in Patients on Hemodialysis. United States: N. p., 2003. Web. doi:10.1007/S00270-003-2705-Y.
Quinn, S.F., E-mail: squinn@peacehealth.org, Kim, J, & Sheley, R C. Transluminally Placed Endovascular Grafts for Venous Lesions in Patients on Hemodialysis. United States. https://doi.org/10.1007/S00270-003-2705-Y
Quinn, S.F., E-mail: squinn@peacehealth.org, Kim, J, and Sheley, R C. 2003. "Transluminally Placed Endovascular Grafts for Venous Lesions in Patients on Hemodialysis". United States. https://doi.org/10.1007/S00270-003-2705-Y.
@article{osti_21088371,
title = {Transluminally Placed Endovascular Grafts for Venous Lesions in Patients on Hemodialysis},
author = {Quinn, S.F., E-mail: squinn@peacehealth.org and Kim, J and Sheley, R C},
abstractNote = {This report summarizes a feasibility study of transluminally placed endovascular grafts (TPEG) using pre-expanded polytetrafluoroethylene (PTFE) to treat venous abnormalities inpatients on hemodialysis. Seventeen patients with peripheral(n = 11) or central (n = 6) venous lesions were treated with TPEG devices. Covered Gianturco stents were used for the peripheral lesions and covered Palmaz stents were used for central lesions. Venous abnormalities included vascular rupture after balloon angioplasty or surgical thrombectomy (n = 4),stenosis associated with an aneurysm (n = 2) and occlusive disease and central stenoses not responsive to balloon angioplasty (n = 11). The mean primary patency period was 37 days. The mean secondary patency period was 215 days. At 60,180, and 360 days the primary and secondary patency rates were 40%,32%, and 32%, and 70%, 55%, and 39%, respectively. Follow-up studies have shown various outcomes of the implanted TPEG devices,which have included stenoses within the TPEG (n = 2),stenoses central to the TPEG (n = 1), stenoses peripheral to the TPEG (n = 3), acute thrombosis extending to the TPEG without a stenosis (n = 1), graft abandoned with patent TPEG (n = 6), and TPEG patent within primary patency period at last follow-up (n =4). The TPEG devices, made with pre-expanded PTFE, appear safe in the short term, do not prevent progressive dialysis access site failure, and need to be compared to PTA and endovascular stenting in a randomized prospective trial.},
doi = {10.1007/S00270-003-2705-Y},
url = {https://www.osti.gov/biblio/21088371}, journal = {Cardiovascular and Interventional Radiology},
issn = {0174-1551},
number = 4,
volume = 26,
place = {United States},
year = {Fri Aug 15 00:00:00 EDT 2003},
month = {Fri Aug 15 00:00:00 EDT 2003}
}